Laboratory characterization of obligate carriers of type 3 von Willebrand disease with a potential role for Platelet Function Analyzer (PFA-200)

被引:2
作者
Geevar, Tulasi [1 ]
Dave, Rutvi Gautam [1 ]
Mathews, Nitty Skariah [1 ]
Kumar, Snehil [1 ]
Mammen, Joy John [1 ]
Vijayan, Ramya [1 ]
Aboobacker, Fouzia N. [2 ]
Abraham, Aby [2 ]
Srivastava, Alok [2 ]
Nair, Sukesh Chandran [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Transfus Med & Immunohematol, Vellore 632004, Tamil Nadu, India
[2] Christian Med Coll & Hosp, Dept Clin Hematol, Vellore, Tamil Nadu, India
关键词
carrier; PFA-100; 200; Type 3 von Willebrand disease; von Willebrand disease; von Willebrand factor; HETEROZYGOUS CARRIERS; HEMORRHAGIC SYMPTOMS; FACTOR DEFICIENCY; CLINICAL UTILITY; BLEEDING HISTORY; BLOOD-GROUP; DIAGNOSIS; MANAGEMENT; RISK; ABO;
D O I
10.1111/ijlh.13787
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Type 3 von Willebrand disease (VWD) is a rare autosomal recessive disorder characterized by undetectable von Willebrand Antigen (VWF:Ag). Carriers of type 3 VWD carry one null allele and have von Willebrand factor (VWF) at about 50% of normal. The aim of this study was to characterize type 3 VWD carriers and to study the role of Platelet Function Analyzer (PFA-200) in this cohort. Methods This was a cross-sectional study where data were collected from carriers (parents/offspring) of type 3 VWD patients and evaluated with activated partial thromboplastin time, factor VIII, blood group, ristocetin cofactor assay (VWF:RCo), VWF:Ag, and closure time on PFA-200 with collagen/epinephrine (COL/EPI), and collagen/ADP (COL/ADP). Results One hundred carriers were included in the study of which 85 were included for PFA-200 analysis. The mean (SD) of VWF:Ag (IU/ml) and VWF:RCo (IU/ml) was 0.63 (0.24) and 0.61 (0.26), respectively. Among the 100 carriers, based on VWF levels (VWF:Ag and/or VWF:RCo) and bleeding history, there were 7 type 1 VWD, 10 type 2 VWD, 25 borderline VWF (0.30-0.50 IU/ml and no bleeding), and 58 normal VWF (>0.50 IU/ml). PFA-200 was prolonged in 71% of the carriers, all carriers with type 1 and type 2 VWD phenotype, 80% carriers with borderline VWF, and 59% with normal VWF. COL/EPI was more sensitive than COL/ADP and showed better correlation with VWF parameters than COL/ADP. Conclusion Carriers of type 3 VWD can have a variable laboratory phenotype. PFA-200 showed good sensitivity among the carriers at VWF levels <0.50 IU/ml.
引用
收藏
页码:603 / 609
页数:7
相关论文
共 34 条
[21]   Characterization of recessive severe type 1 and 3 von Willebrand disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD [J].
Michiels, Jan Jacques ;
Berneman, Zwi ;
Gadisseur, Alain ;
van der Planken, Marc ;
Schroyens, Wilfried ;
van de Velde, Ann ;
van Vliet, Huub .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2006, 12 (03) :277-295
[22]   THE ROLE OF PLATELET VON-WILLEBRAND-FACTOR IN PLATELET-ADHESION AND THROMBUS FORMATION - A STUDY OF 34 PATIENTS WITH VARIOUS SUBTYPES OF TYPE-I VON-WILLEBRAND DISEASE [J].
FRESSINAUD, E ;
FEDERICI, AB ;
CASTAMAN, G ;
ROTHSCHILD, C ;
RODEGHIERO, F ;
BAUMGARTNER, HR ;
MANNUCCI, PM ;
MEYER, D .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (02) :327-332
[23]   Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A [J].
Sood, S. L. ;
Cuker, A. ;
Wang, C. ;
Metjian, A. D. ;
Chiang, E. Y. ;
Soucie, J. M. ;
Konkle, B. A. .
HAEMOPHILIA, 2013, 19 (04) :595-601
[24]   Platelet morphological changes in 2 patients with von Willebrand disease type 3 caused by large homozygous deletions of the von Willebrand factor gene [J].
Nurden, Paquita ;
Nurden, Alan T. ;
La Marca, Silvia ;
Punzo, Margherita ;
Baronciani, Luciano ;
Federici, Augusto B. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (11) :1627-1629
[25]   Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease in southern Iran [J].
Shamsakhzari, Shoeleh ;
Afrasiabi, Abdolreza ;
Haghpanah, Sezaneh ;
Karimi, Mehran .
BLOOD COAGULATION & FIBRINOLYSIS, 2011, 22 (04) :325-330
[26]   Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease [J].
Baronciani, L ;
Cozzi, G ;
Canciani, MT ;
Peyvandi, F ;
Srivastava, A ;
Federici, AB ;
Mannucci, PM .
THROMBOSIS AND HAEMOSTASIS, 2000, 84 (04) :536-540
[27]   Risk of perinatal intracranial hemorrhage and role of prenatal genetic testing in individuals with type 3 von Willebrand disease [J].
Warad, Deepti ;
Ismail, Maryama ;
Rusk, Dawn ;
Rodriguez, Vilmarie ;
Pruthi, Rajiv K. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (10) :2779-2780
[28]   Phenotypic and genotypic characterization of 10 Finnish patients with von Willebrand disease type 3: discovery of two main mutations [J].
Jokela, V. ;
Lassila, R. ;
Szanto, T. ;
Joutsi-Korhonen, L. ;
Armstrong, E. ;
Oyen, F. ;
Schneppenheim, S. ;
Schneppenheim, R. .
HAEMOPHILIA, 2013, 19 (06) :E344-E348
[29]   Laboratory Diagnosis of von Willebrand Disease Type 1/2E (2A Subtype IIE), Type 1 Vicenza and Mild Type 1 Caused by Mutations in the D3, D4, B1-B3 and C1-C2 Domains of the von Willebrand Factor Gene Role of von Willebrand Factor Multimers and the von Willebrand Factor Propeptide/Antigen Ratio [J].
Gadisseur, Alain ;
Berneman, Zwi ;
Schroyens, Wilfried ;
Michiels, Jan Jacques .
ACTA HAEMATOLOGICA, 2009, 121 (2-3) :128-138
[30]   A new case of platelet-type von Willebrand disease supports the recent findings of gain-of-function GP1BA variants outside the C-terminal disulphide loop enhances affinity for von Willebrand factor [J].
Monteiro, Catarina ;
Goncalves, Ana ;
Pereira, Monica ;
Lau, Catarina ;
Morais, Sara ;
Santos, Rosario .
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (04) :673-677